Edition:
India

Dr.Reddy's Laboratories Ltd (REDY.BO)

REDY.BO on Bombay Stock Exchange

3,189.75INR
3:40pm IST
Change (% chg)

Rs-1.70 (-0.05%)
Prev Close
Rs3,191.45
Open
Rs3,181.25
Day's High
Rs3,217.00
Day's Low
Rs3,181.00
Volume
11,294
Avg. Vol
35,092
52-wk High
Rs4,382.95
52-wk Low
Rs2,750.00

REDY.BO

Chart for REDY.BO

About

Dr. Reddy's Laboratories Limited is a pharmaceutical company that is engaged in providing medicines. The Company operates in three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment includes manufacturing and marketing prescription and... (more)

Overall

Beta: 0.29
Market Cap(Mil.): Rs546,246.81
Shares Outstanding(Mil.): 170.72
Dividend: 20.00
Yield (%): 0.63

Financials

  REDY.BO Industry Sector
P/E (TTM): -- 36.26 36.23
EPS (TTM): -- -- --
ROI: -- 14.29 13.79
ROE: -- 15.13 14.74

BRIEF-DR. Reddy's laboratories says launch of Bupropion HCL extended-release tablets, USP (sr) in U.S. market

* Launch of bupropion hcl extended-release tablets, usp (sr) in u.s. Market Source text for Eikon: Further company coverage:

02 Sep 2016

BUZZ-India's Dr. Reddy's Labs falls on poor June-qtr results

** Shares of Dr. Reddy's Laboratories fall as much as 9.9 pct to lowest since May 16

27 Jul 2016

BUZZ-India's Dr. Reddy's Labs falls ahead of earnings

** Drugmaker Dr. Reddy's Laboratories Ltd falls as much as 3.75 pct in its biggest pct loss in nearly four months

25 Jul 2016

India's Dr Reddy's in $350 million deal to buy eight U.S. drugs from Teva, Allergan

MUMBAI India's second-largest drugmaker Dr Reddy's Laboratories Ltd said it agreed to buy eight generic drugs from Teva Pharmaceutical Industries and Allergan Plc for $350 million in cash to bolster its U.S. business.

11 Jun 2016

BUZZ-India's Dr Reddy's falls; U.S. agency charges firm for packaging lapses

** Drugmaker Dr.Reddy's Laboratories Ltd falls as much as 2.4 pct to its lowest since May 26

09 Jun 2016

MEDIA-US Agency charges India's Dr. Reddy's for packaging lapses; co disagrees - Economic Times

- Note: Reuters has not verified this story and does not vouch for its accuracy

09 Jun 2016

BRIEF-Spectrum Pharma says Dr Reddy's will be permitted to market generic version of Folotyn in US on Dec 1, 2022 or earlier

* Co's unit, dr. Reddy's labs, ltd entered into settlement agreement to resolve their patent litigation relating to folotyn

31 May 2016

India's Dr Reddy's falls on weak results, Deutsche Bank forecast cut

** India's second largest drugmaker on Thursday posted a near 86 pct slump in March-quarter profit

13 May 2016

Earnings vs. Estimates